# A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

> **NCT05706506** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 152 (actual)

## Conditions studied

- Type 2 Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Tirzepatide

## Key facts

- **NCT ID:** NCT05706506
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-08
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-10-31
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05706506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05706506, "A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05706506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*